|
1
|
Siegel RL, Miller KD, Wagle NS and Jemal
A: Cancer statistics, 2023. Cancer J Clinicians. 73:17–48. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zauber AG, van Ballegooijen M and Schapiro
M: Colonoscopic polypectomy and Long-term prevention of
Colorectal-cancer deaths. N Engl J Med. 366:687–696. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schmitt M and Greten FR: The inflammatory
pathogenesis of colorectal cancer. Nat Rev Immunol. 21:653–667.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu Y, Chen Y, Wang F, Lin J, Tan X, Chen
C, Wu LL, Zhang X, Wang Y, Shi Y, et al: Caveolin-1 promotes glioma
progression and maintains its mitochondrial inhibition resistance.
Discov Oncol. 14:1612023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yamamoto T, Kawada K and Obama K:
Inflammation-related biomarkers for the prediction of prognosis in
colorectal cancer patients. Int J Mol Sci. 22:80022021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang H, Shi Y, Ying J, Chen Y, Guo R,
Zhao X, Jia L, Xiong J and Jiang F: A bibliometric and visualized
research on global trends of immune checkpoint inhibitors related
complications in melanoma, 2011–2021. Front Endocrinol.
14:11646922023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li MX, Liu XM, Zhang XF, Zhang JF, Wang
WL, Zhu Y, Dong J, Cheng JW, Liu ZW, Ma L and Lv Y: Prognostic role
of neutrophil-to-lymphocyte ratio in colorectal cancer: A
systematic review and meta-analysis: Neutrophil-to-Lymphocyte Ratio
in Colorectal Cancer. Int J Cancer. 134:2403–2413. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gu L, Li H, Chen L, Ma X, Li X, Gao Y,
Zhang Y, Xie Y and Zhang X: Prognostic role of lymphocyte to
monocyte ratio for patients with cancer: Evidence from a systematic
review and meta-analysis. Oncotarget. 7:319262016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Turan YB: The prognostic importance of the
pan-immune-inflammation value in patients with septic shock. BMC
Infect Dis. 24:692024. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cheng Z, Luo Y, Zhang Y, Wang Y, Chen Y,
Xu Y, Peng H and Zhang G: A novel NAP1L4/NUTM1 fusion arising from
translocation t(11;15)(p15;q12) in a myeloid neoplasm with
eosinophilia and rearrangement of PDGFRA highlights an unusual
clinical feature and therapeutic reaction. Ann Hematol.
99:1561–1564. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fucà G, Guarini V, Antoniotti C, Morano F,
Moretto R, Corallo S, Marmorino F, Lonardi S, Rimassa L,
Sartore-Bianchi A, et al: The pan-immune-inflammation value is a
new prognostic biomarker in metastatic colorectal cancer: Results
from a pooled-analysis of the Valentino and TRIBE first-line
trials. Br J Cancer. 123:403–409. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Corti F, Lonardi S, Intini R, Salati M,
Fenocchio E, Belli C, Borelli B, Brambilla M, Prete AA, Quarà V, et
al: The pan-immune-inflammation value in microsatellite
instability-high metastatic colorectal cancer patients treated with
immune checkpoint inhibitors. Eur J Cancer. 150:155–167. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang XC, Liu H, Liu DC, Tong C, Liang XW
and Chen RH: Prognostic value of pan-immune-inflammation value in
colorectal cancer patients: A systematic review and meta-analysis.
Front Oncol. 12:10368902022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Baba Y, Nakagawa S, Toihata T, Harada K,
Iwatsuki M, Hayashi H, Miyamoto Y, Yoshida N and Baba H:
Pan-immune-inflammation value and prognosis in patients with
esophageal cancer. Ann Surg Open. 3:e1132022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Şahin AB, Cubukcu E, Ocak B, Deligonul A,
Oyucu Orhan S, Tolunay S, Gokgoz MS, Cetintas S, Yarbas G, Senol K,
et al: Low pan-immune-inflammation-value predicts better
chemotherapy response and survival in breast cancer patients
treated with neoadjuvant chemotherapy. Sci Rep. 11:146622021.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shi J, Liu C, Yang N and Qiu C:
Pan-immune-inflammation value: A new prognostic index in operative
laryngeal and pharyngeal carcinomas. Clin Transl Oncol. 27:151–159.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ligorio F, Fucà G, Zattarin E, Lobefaro R,
Zambelli L, Leporati R, Rea C, Mariani G, Bianchi GV, Capri G, et
al: The Pan-immune-inflammation-value predicts the survival of
patients with human epidermal growth factor receptor 2
(HER2)-positive advanced breast cancer treated with first-line
Taxane-trastuzumab-pertuzumab. Cancers (Basel). 13:19642021.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th Edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Buonacera A, Stancanelli B, Colaci M and
Malatino L: Neutrophil to lymphocyte Ratio: An emerging marker of
the relationships between the immune system and diseases. Int J Mol
Sci. 23:36362022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tao BF, Zhu HQ, Qi LN, Zhong JH, Mai R and
Ma L: Preoperative monocyte-to-lymphocyte ratio as a prognosis
predictor after curative hepatectomy for intrahepatic
cholangiocarcinoma. BMC Cancer. 24:11792024. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gasparyan AY, Ayvazyan L, Mukanova U,
Yessirkepov M and Kitas GD: The Platelet-to-Lymphocyte ratio as an
inflammatory marker in rheumatic diseases. Ann Lab Med. 39:3452019.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wesselink E, Balvers MGJ, Kok DE, Winkels
RM, van Zutphen M, Schrauwen RWM, Keulen ETP, Kouwenhoven EA,
Breukink SO, Witkamp RF, et al: Levels of inflammation markers are
associated with the risk of recurrence and All-cause mortality in
patients with colorectal cancer. Cancer Epidemiol Biomarkers Prev.
30:1089–1099. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen Y, Zhang Y, Wang Z, Wang Y, Luo Y,
Sun N, Zheng S, Yan W, Xiao X, Liu S, et al: CHST15 gene germline
mutation is associated with the development of familial
myeloproliferative neoplasms and higher transformation risk. Cell
Death Dis. 13:5862022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu Y, Zhao S, Chen Y, Ma W, Lu S, He L,
Chen J, Chen X, Zhang X, Shi Y, et al: Vimentin promotes glioma
progression and maintains glioma cell resistance to oxidative
phosphorylation inhibition. Cell Oncol. 46:1791–1806. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Quail DF, Amulic B, Aziz M, Barnes BJ,
Eruslanov E, Fridlender ZG, Goodridge HS, Granot Z, Hidalgo A,
Huttenlocher A, et al: Neutrophil phenotypes and functions in
cancer: A consensus statement. J Exp Med. 219:e202200112022.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Apte RN, Dotan S, Elkabets M, White MR,
Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y and Voronov E: The
involvement of IL-1 in tumorigenesis, tumor invasiveness,
metastasis and tumor-host interactions. Cancer Metastasis Rev.
25:387–408. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang HJ, Wang HY, Zhang HT, Su JM, Zhu J,
Wang HB, Zhou WY, Zhang H, Zhao MC, Zhang L and Chen XF:
Transforming growth factor-β1 promotes lung adenocarcinoma invasion
and metastasis by epithelial-to-mesenchymal transition. Mol Cell
Biochem. 355:309–314. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shapaer T, Chen Y, Pan Y, Wu Z, Tang T,
Zhao Z and Zeng X: Elevated BEAN1 expression correlates with poor
prognosis, immune evasion, and chemotherapy resistance in rectal
adenocarcinoma. Discov Oncol. 15:4462024. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Engblom C, Pfirschke C and Pittet MJ: The
role of myeloid cells in cancer therapies. Nat Rev Cancer.
16:447–462. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Olingy CE, Dinh HQ and Hedrick CC:
Monocyte heterogeneity and functions in cancer. J Leukoc Biol.
106:309–322. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wu Z, Chen Y, Yu G and Ma Y: Research
trends and hotspots in surgical treatment of recurrent
nasopharyngeal carcinoma: A bibliometric analysis from 2000 to
2023. Asian J Surg. 47:2939–2941. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ugel S, Canè S, De Sanctis F and Bronte V:
Monocytes in the tumor microenvironment. Annu Rev Pathol.
16:93–122. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li J, Wu Z, Pan Y, Chen Y, Chu J, Cong Y
and Fang Q: GNL3L exhibits pro-tumor activities via NF-κB pathway
as a poor prognostic factor in acute myeloid leukemia. J Cancer.
15:4072–4080. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yin L, Xie S, Chen Y, Li W, Jiang X, Li H,
Li J, Wu Z, Xiao X, Zhang G, et al: Novel germline mutation KMT2A
G3131S confers genetic susceptibility to familial
myeloproliferative neoplasms. Ann Hematol. 100:2229–2240. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Contursi A, Grande R, Dovizio M, Bruno A,
Fullone R and Patrignani P: Platelets in cancer development and
diagnosis. Biochem Soc Trans. 46:1517–1527. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang F, Wu Z, Sun S, Fu Y, Chen Y and Liu
J: POEMS syndrome in the 21st century: A bibliometric analysis.
Heliyon. 9:e206122023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Palacios-Acedo AL, Mège D, Crescence L,
Dignat-George F, Dubois C and Panicot-Dubois L: Platelets,
Thrombo-inflammation, and cancer: Collaborating with the enemy.
Front Immunol. 10:18052019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rothwell PM, Wilson M, Price JF, Belch
JFF, Meade TW and Mehta Z: Effect of daily aspirin on risk of
cancer metastasis: A study of incident cancers during randomised
controlled trials. Lancet. 379:1591–1601. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Algra AM and Rothwell PM: Effects of
regular aspirin on Long-term cancer incidence and metastasis: A
systematic comparison of evidence from observational studies versus
randomised trials. Lancet Oncol. 13:518–527. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Burn J, Gerdes AM, Macrae F, Mecklin JP,
Moeslein G, Olschwang S, Eccles D, Evans DG, Maher ER, Bertario L,
et al: Long-term effect of aspirin on cancer risk in carriers of
hereditary colorectal cancer: An analysis from the CAPP2 randomised
controlled trial. Lancet. 378:2081–2087. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gupta D and Lis CG: Pretreatment serum
albumin as a predictor of cancer survival: A systematic review of
the epidemiological literature. Nutrition J. 9:692010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Rosenberg SA: Progress in human tumour
immunology and immunotherapy. Nature. 411:380–384. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Takahashi T, Kuniyasu Y, Toda M, Sakaguchi
N, Itoh M, Iwata M, Shimizu J and Sakaguchi S: Immunologic
self-tolerance maintained by CD25+CD4+ naturally anergic and
suppressive T cells: Induction of autoimmune disease by breaking
their anergic/suppressive state. Int Immunol. 10:1969–1980. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shayimu P, Awula M, Wang CY, Jiapaer R,
Pan YP, Wu ZM, Chen Y and Zhao ZL: Serum nutritional predictive
biomarkers and risk assessment for anastomotic leakage after
laparoscopic surgery in rectal cancer patients. World J
Gastrointest Surg. 16:3142–3154. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhao H, Chen X, Zhang W, Cheng D, Lu Y,
Wang C, Li J, You L, Yu J, Guo W, et al: Pan-immune-inflammation
value is associated with the clinical stage of colorectal cancer.
Front Surg. 9:9968442022. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Pérez-Martelo M, González-García A,
Vidal-Ínsua Y, Blanco-Freire C, Brozos-Vázquez EM,
Abdulkader-Nallib I, Álvarez-Fernández J, Lázare-Iglesias H,
García-Martínez C, Betancor YZ, et al: Clinical significance of
baseline Pan-immune-inflammation value and its dynamics in
metastatic colorectal cancer patients under first-line
chemotherapy. Sci Rep. 12:68932022. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Seo YJ, Kim KE, Jeong WK, Baek SK and Bae
SU: Effect of preoperative pan-immune-inflammation value on
clinical and oncologic outcomes after colorectal cancer surgery: A
retrospective study. Ann Surg Treat Res. 106:169–177. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhang Y, Yan N, Feng Y, Wu Y, Sun Y, Gao
X, Gu C, Ma X, Gao F, Zhang H and Zhou J: Inflammatory markers
predict efficacy of immunotherapy in advanced non-small cell lung
cancer: A preliminary exploratory study. Discov Oncol. 16:82025.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lin F, Zhang LP, Xie SY, Huang HY, Chen
XY, Jiang TC, Guo L and Lin HX: Pan-immune-inflammation value: A
new prognostic index in operative breast cancer. Front Oncol.
12:8301382022. View Article : Google Scholar : PubMed/NCBI
|
